Results 161 to 170 of about 43,486 (267)

Specific Glucagon Assay System Using a Receptor-Derived Glucagon-Binding Peptide Probe. [PDF]

Int J Mol Sci
Shigeto H, Suzuki Y, Yamamura S.
europepmc   +1 more source

Multifaceted burden of short bowel syndrome for patients and caregivers: The landmark survey

Nutrition in Clinical Practice, EarlyView.
Abstract Background Short bowel syndrome is a debilitating condition often requiring long‐term parenteral support to maintain hydration, nutrition, and survival. Methods As part of the noninterventional, cross‐sectional Landmark Survey study, we evaluated burdens associated with short bowel syndrome and parenteral support dependency from patient and ...
Jenny E. Harrison, Syed‐Mohammed Jafri, Roopa Vemulapalli, Vanessa Kumpf, Gail Mitchell, Mena Boules, Mindy M. Yang, Laurin Jackson, Jinyi Wang, Laurie Zografos, Daniel Wolin, Marion F. Winkler   +11 more
wiley   +1 more source

GLP-1 Agonist Attenuates Nicotine Reward-Related Behavior by Regulating the Prepro-Orexin in the Hypothalamus and Prepro-Glucagon in the Nucleus Tractus Solitarius. [PDF]

Behav Neurol
Rahmadi M, Ardianto C, Rodsiri R, Anggraini D, Firdaussy APSA, Sumartha INB, Nurhan AD.   +6 more
europepmc   +1 more source

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart, Liam Gallagher, Bridget Ebert, Samir S. Khariwala   +3 more
wiley   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. [PDF]

Indian J Med Res
Gupta M, Shukla J.
europepmc   +1 more source

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

Obesity, EarlyView.
ABSTRACT The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses ...
Fernanda Baeza Scagliusi, Bruno Gualano, Pernille Andreassen, Cindi SturtzSreetharan, Sissel Due Jensen, Alexandra Brewis   +5 more
wiley   +1 more source

The expanding landscape of the glucagon signaling network: mechanisms and outcomes.

Endocrinology
Foollee A, Wu Y, Rusu PM, Rose AJ.
europepmc   +1 more source

Successful Resuscitation of Anaphylactic Shock With Central Nervous System Dysfunction in a Patient on Multiple Antihypertensive Therapies: A Case Report and Literature Review. [PDF]

Cureus
Kashimura Y, Hara K, Shiojima H, Oki M, Ueno K.   +4 more
europepmc   +1 more source

Incidental Resolution of Dopamine Agonist Induced Impulse Control Disorder with GLP‐1 Receptor Agonist

Movement Disorders Clinical Practice, EarlyView.
Hannah Kelly, Thomas Davis
wiley   +1 more source